The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
Abstract
The adoptive transfer of tumor-infiltrating lymphocytes (TIL) expanded in interleukin-2 (IL-2) to mice bearing micrometastases from various types of tumors showed that TIL are 50 to 100 times more effective in their therapeutic potency than are lymphokine-activated killer (LAK) cells. Therefore the use of TIL was explored for the treatment of mice with large pulmonary and hepatic metastatic tumors that do not respond to LAK cell therapy. Although treatment of animals with TIL alone or cyclophosphamide alone had little impact, these two modalities together mediated the elimination of large metastatic cancer deposits in the liver and lung. The combination of TIL and cyclophosphamide was further potentiated by the simultaneous administration of IL-2. With the combination of cyclophosphamide, TIL, and IL-2, 100% of mice ( n = 12) bearing the MC-38 colon adenocarcinoma were cured of advanced hepatic metastases, and up to 50% of mice were cured of advanced pulmonary metastases. Techniques have been developed to isolate TIL from human tumors. These experiments provide a rationale for the use of TIL in the treatment of humans with advanced cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Self-citationGrimm, E. A., Mazumder, A., Zhang, H. Z., & Rosenberg, S. A. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.6.1823 · Cited by 2,204
Self-citationA generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship
BRESLOW, N. (1970) · Biometrika · doi:10.1093/biomet/57.3.579 · Cited by 1,411
Mulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Self-citationLysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
Lotze, M. T., Grimm, E. A., Mazumder, A., Strausser, J. L., & Rosenberg, S. A. (1981) · PubMed · Cited by 523
Self-citationLafrenière, R., & Rosenberg, S. A. (1985) · PubMed · Cited by 380
Self-citationBerendt, M. J., & North, R. J. (1980) · The Journal of experimental medicine · doi:10.1084/jem.151.1.69 · Cited by 369
Lymphokine-activated killer cells: A new approach to immunotherapy of cancer
(1985) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/75.4.595 · Cited by 308
Rosenstein, M., Yron, I., Kaufmann, Y., & Rosenberg, S. A. (1984) · PubMed · Cited by 297
Self-citationThe anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé, J. J., Shu, S., & Rosenberg, S. A. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.1.646 · Cited by 294
Self-citationYron, I., Wood, T. A., Spiess, P. J., & Rosenberg, S. A. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.1.238 · Cited by 264
Self-citationPassive Immunotherapy of Cancer in Animals and Man
(1977) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60637-5 · Cited by 243
Adoptive immunotherapy of newly induced murine sarcomas.
Shu, S., & Rosenberg, S. A. (1985) · PubMed · Cited by 136
Self-citationAdoptive immunotherapy of cancer: accomplishments and prospects.
Rosenberg, S. A. (1984) · PubMed · Cited by 120
Self-citationSpecificity of adoptive chemoimmunotherapy of established syngeneic tumors.
Cheever, M. A., Greenberg, P. D., & Fefer, A. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.2.711 · Cited by 118
Fernández‐Cruz, E., Halliburton, B. L., & Feldman, J. D. (1979) · The Journal of Immunology · doi:10.4049/jimmunol.123.4.1772 · Cited by 62
Cited by
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Self-citationZhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Self-citationCancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citation
Metadata
- Authors
- Rosenberg, S. A., Spiess, P., & Lafreniere, R.
- Venue
- Science
- Published
- 1986-09-19
- Volume
- 233
- Issue
- 4770
- Pages
- 1318-1321
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2089828715
- Cited by
- 1,880
- References
- 16
- FWCI
- 26.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.